Basilea Pharmaceutica AG's EBIT is $120M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Basilea Pharmaceutica AG (BSLN.SW) currently reports a EBIT of $120M as of June 2026. That compares with $66M in the prior-year period — up 87.9% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Basilea Pharmaceutica AG's EBIT history and peer comparisons.
Basilea Pharmaceutica AG's EBIT increased from $66M to $120M — a 87.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Basilea Pharmaceutica AG's EBIT of $120M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Basilea Pharmaceutica AG reported $120M in EBIT as of June 2026. That compares with $66M in the prior-year period — up 87.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Basilea Pharmaceutica AG, and consider following BSLN.SW for alerts when major investors trade the stock.